Clinical trials: Gastrointestinal Dysmotility
Autoimmune Gastrointestinal Dysmotility
Novel Antineuronal Antibodies in Gastrointestinal Motility Disorders
Gastrointestinal motility disorders represent a heterogeneous group of neuromuscular diseases of the enteric nervous systems. While autoimmune neuromuscular diseases of the central nervous system (CNS) are well described, the…
- Trial name
- NCT04872439
- Testing
- Blood sample collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Johns Hopkins University
Gastrointestinal Dysmotility
Enteric Neural Precursor Cells (ENPC) in the Human Gut
The study aim is to acquire human tissues to (a) understand the structure and organization of the human Enteric Nervous System; (b) perform a molecular transcriptomic profile of individual cells residing in the human gut; (c)…
- Trial name
- NCT04880538
- Testing
- Endoscopic procedure
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Small Fiber Neuropathy, Gastrointestinal Dysmotility
Analysis of Cutaneous Nerve Biopsies in Gastrointestinal Motility Disorders
This study is being done to evaluate cutaneous nerve biopsies from patients with refractory gastrointestinal motility disorders.
- Trial name
- NCT04872452
- Testing
- Skin biopsy
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Gastrointestinal Dysmotility
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
- Trial name
- NCT01280344
- Testing
- Saline Solution for Injection, Ipamorelin
- Where
- 45 sites in United States
- Volunteers
- 320 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Gastrointestinal Dysmotility
Ulimorelin Study of Efficacy and Safety (ULISES 007)
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.
- Trial name
- ULISES (NCT01285570)
- Testing
- Ulimorelin Intravenously (IV), 5% dextrose in water
- Where
- 45 sites in United States, Hungary and 5 more
- Volunteers
- 332 people
- Sponsor
- Tranzyme, Inc.
Gastrointestinal Dysmotility
Ulimorelin Study of Efficacy and Safety (ULISES 008)
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection
- Trial name
- NCT01296620
- Testing
- Ulimorelin Intravenously (IV), Ulimorelin Invtravenously (IV), 5% dextrose in water
- Where
- 50 sites in United States, Bulgaria and 4 more
- Volunteers
- 330 people
- Sponsor
- Tranzyme, Inc.